Form 4: Nuvation Bio Inc. Officer Dongfang Liu Reports Stock Transactions

Chief Medical Officer Dongfang Liu of Nuvation Bio Inc. reports the acquisition and disposal of Class A Common Stock on May 2, 2025, according to a Form 4 filing with the SEC.

Summary

• On May 2, 2025, Dongfang Liu, Chief Medical Officer of Nuvation Bio Inc., engaged in transactions involving the company's Class A Common Stock.
• Liu acquired 20,000 shares of Class A Common Stock at a price of $1.94 per share through the exercise of stock options.
• Simultaneously, Liu disposed of 20,000 shares of Class A Common Stock at a weighted-average price of $2.5012 per share.
• Following these transactions, Liu directly owns 12,000 shares of Class A Common Stock.
• Liu also holds options to purchase 480,000 shares of Class A Common Stock at an exercise price of $1.94.
• The sale of shares was conducted pursuant to a pre-arranged 10b5-1 trading plan established on October 10, 2024.
• A Power of Attorney was granted on March 19, 2025, authorizing Philippe Sauvage, Moses Makunje, and Stephen Dang to act on Liu's behalf for SEC filings related to Nuvation Bio Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there's no indication of unusual activity or concern.

Positives

• The exercise of stock options indicates confidence in the company's future prospects.
• The sale of shares at a price higher than the exercise price resulted in a profit for the reporting person.

Negatives

• The sale of shares, even under a 10b5-1 plan, could be interpreted negatively by some investors.

Risks

• The market's reaction to insider selling, even if pre-planned, can be unpredictable.
• Changes in the company's performance or outlook could affect the value of the remaining shares and options held by the reporting person.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on their interpretation of insider selling activity.
• Employees may be indirectly affected by the market's perception of the company's stock.

Key Dates

Keywords

Nuvation Bio Inc., insider trading, Form 4, Dongfang Liu, stock options, Class A Common Stock, 10b5-1 plan, SEC filing